return equiti ttm
follow zoetiss second-quart earn releas tuesday morn august
increas ep target ep target
overal number ahead estim compani expect
organ growth roughli basi point impress anoth
strong quarter execut includ continu strong growth compani
dermatolog portfolio manag abil navig pocket challeng end-
market livestock segment longer term believ new product
allow compani consist outpac rate broader anim health spend
maintain outperform rate zoeti given stabil busi model
prospect double-digit earn growth beyond
innov manag commentari combin flea tick heartworm
product simparica trio quit posit compani expect full approv
eu next month hope launch product unit state among
geographi earli potenti zoeti first unit state
combin product testament compani innov mark
improv compar underweight posit parasiticid time
ipo compani also indic file monoclon antibodi product
cat unit state eu expect approv zoeti
addit mab candid nexvet portfolio dog may continu boost
compani growth new product futur
companion anim apoquel cytopoint combin million revenu
second quarter second consecut quarter year-over-year growth see exhibit
total million sequenti manag note simparica gener
million repres oper growth continu view simparica
trio signific opportun growth beyond expect simparica
trio add addit layer growth beyond compani current simparica flea
tick product proheart recent proheart product introduct key
question move forward opinion whether invest build
commerci footprint lead rebound abaxi diagnost busi
zoeti leader develop manufactur market anim health medicin vaccin
product companion anim market annual revenu exceed billion compani found
divis spun februari oper countri maintain one
largest budget industri
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
exhibit quarterli apoquel cytopoint sale present
exhibit companion anim organ growth geographi present
livestock livestock busi exceed expect quarter organ compar estim
declin poultri busi benefit shift antibiot altern well gener faster
consumpt growth rate world-wide compar swine cattl find quit tell even despit higher
impact african swine fever asf compani expect million hit compar million hit
previouslyzoeti success grow livestock busi full year model
intern livestock flat organ basi compar prior estim view potenti
diagnost livestock space long term potenti add nice top-lin growth although
busi invest mode next year
xxsourc compani report compani report william blair compani report william blair william blair
exhibit livestock organ growth speci present
exhibit livestock organ growth geographi present
increas full-year revenu target million billion result
increas organ growth target basi point increas ep target
increas revenu target million result increas companion organ
growth target increas ep estim
valuat stock thought
zoeti trade time updat ep estim time updat estim
compar five-year averag time forward earn anim health manufactur peer
time ep time ep maintain outperform rate zoeti despit valuat
premium given solid all-around result expect pipelin product extend industry-
averag revenu growth summari revis model found exhibit
view follow key risk zoeti next three five year slowdown economi
neg affect spend companion anim livestock diseas outbreak shift away usag
antibiot food anim shift away meat consumpt develop market due chang
xxsourc compani report william blair otherxxsourc compani report william blair william blair
good gross gener research amort intang total oper oper expense/ incom pre-tax tax net loss attribut non-controlling interest- net incom excl non-recurring non-recurring item net net ep excl non-recurring per average share outstand margin analysi gross metric total revenu constant oper revenu constant incom excl non-recur excl non-recur share blair compani estimatesourc compani report william blair compani llc estim import disclosur
